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New test accurately predicts which family members
will develop thyroid cancer

Genetic testing: a new paradigm for
medullary thyroid carcinoma
Lab to Clinic

Robert F. Gagel is chief of
the Endocrine Section of
the Division of Medicine

When Cathy Parker was ten years old, her life
changed forever. She lost her mother to pheochromocytoma, a neoplastic adrenal disorder
known to occur as part of a clinical syndrome
called multiple endocrine neoplasia type 2, or
MEN 2, which also encompasses parathyroid
neoplasia and medullary thyroid carcinoma, or
MTC. While struggling with the loss of her
mother, Cathy learned that the syndrome is hereditary and that she stood a 50 percent chance of
having inherited it herself.
Pheochromocytoma and MTC are the most
threatening of these diseases, said Robert F. Gagel,
M.D., chief of the Endocrine Section of The
University of Texas M. D. Anderson Cancer
Center. Medullary thyroid carcinoma develops in
over 90% of individuals who inherit MEN 2, and
the death rate from MTC that has spread to other
parts of the body is 15 to 25 percent. Pheochromocytoma may cause high blood pressure, heart
irregularities, or even death if not treated. The
parathyroid tumors are generally benign but may
cause blood calcium levels to be elevated.

Screening tests not definitive
After her mother's death, Cathy (not her real
name) was checked annually for signs of these
three disorders, as were individuals from many
o er
es own or e eve to e ecte
by MEN 2. This screening included a pentagastrin
or a combined pentagastrin/calcium test, which
detects early abnormal elevations in calcitonin
level, a sign of MTC; serum or urine catechola mine measurements to detect early adrenal medullary abnormalities, which often accompany
MTC; and serum calcium measurements to detect parathyroid abnormalities. Although these
tests are useful in identifying these tumors at

early, treatable stages, they are far from definitive:
the pentagastrin test, for example, has a high
false-positive rate, meaning that some patients
who did not actually have MTC have been treated
unnecessarily.
For patients with MTC, that treatment means
surgery, complete removal of the thyroid gland.
The only outward sign of this surgery is a small
scar on the neck that fades with time; regular,
lifelong hormone replacement therapy allows most
patients to live a normal life. One to three percent
of patients who undergo this surgery have a low
blood level of calcium, necessitating calcium and
vitamin D supplementation, or develop hoarseness, suggesting that the procedure can damage
the vocal cords.
Cathy's diagnosis came when she was 18. For
the first time, the screening tests detected an
ele ated calcitonin level, indicating MTC. Her
thyroid gland was removed shortly after, and she
was believed cured. Meanwhile, however, endocrinologists treating patients with MTC found
evidence of metastasis in children as young as six
years old. They began to realize that, for many
patients, even adolescence was too late for the
surgery, and that the thyroid should be removed
much earlier, preferably in its hyperplastic or
precancerous state, to prevent metastasis. They
were m a quan ary: ear er surgery was c ear y
indicated, yet they could not operate until they
had clinical evidence of disease, an elevated calcitonin level. A new test that would detect the
disease earlier and more accurately was needed.
Researchers at M. D. Anderson and other institutions believed that the best hope for individuals
with the hereditary form of MTC was a test that
could detect the genetic abnormality that causes
the disease.
continued on page 2
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Cathy grew up, married, had children. At one
of her regular check-ups-standard for people
who have been treated for cancer-Cathy was
found to again have an elevated calcitonin level,
a sign of metastatic disease. She has no signs of
the metastasis, however, and without further treatment remains well. Her younger brother, who
also had a thyroidectomy as an adolescent and
was later found to have metastatic disease, is not
so lucky. He has severe symptoms and is being
aggressively treated.
Genetic analysis key to early detection
While Cathy was raising her children, researchers at M. D. Anderson and other institutions were
conducting the painstaking genetic research that
would allow development of a test that could
detect the genetic abnormality long before the
disease was detectable clinically. Wanting to spare
her children her brother's fate, Cathy and her
family helped by supplying blood samples on
request to Gagel and his colleague, Gilbert Cote,
Ph.D., of the Endocrine Section. Eventually the
abnormality was discovered to be a DNA mutation in a gene called RET.
When, in 1993, a blood test for this mutation
finally became available, Cathy's children were
nine and eleven years old and neither had shown
any signs of MEN 2. The Parkers decided to have
their children tested immediately by the new,
more sensitive test. Said Cathy, "We welcomed
the opportunity to know for sure. If either of the
children were affected, we wanted to know as
·soon as possible so we could take immediate
action." Gagel affirmed their choice: "We now
can determine with nearly 100 percent accuracy
whether a child with an affected parent has the
RET mutation. We also know that 90 to 95
percent of children who have the mutation will
go on to develop MTC. This gives us more
accurate information for clinical decision-making
and is a logical extension of earlier efforts to
detect the tumor before it spreads."
The evaluation of DNA in
peripheral blood from
Cathy Parker (e) and her
two children demonstrates
that she and her son (■)
carry a "mutant" copy of
the RET protooncogene as
well as a normal copy,
indicating that both are
likely to develop medullary
thyroid cancer. The
daughter (0) has only a
normal ~opy, indicating
that she is not at risk for
development of this tumor.
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All the same, when the Parkers learned that
the younger child, a boy, was affected, "it hit like
a ton of bricks," recalled Cathy. "It worked as it
was supposed to: one child had it, one didn't,"
she said, referring to the autosomal pattern of
inheritance that gives each child a 50-50 chance
ofinheriting the mutation that causes the disease.
The Parkers then faced the choice of whether to
have their son's thyroid removed . Gagel and his
surgeon colleagues recommended thyroidectomy.
They believe that thyroidectomy is the best choice
for patients who carry the mutation, and they are
glad to be able to finally offer a test that can give
an early and highly accurate prediction of an
individual's risk of developing MTC. The Parkers
chose thyroidectomy for their son.
To test or not to test
Some parents choose not to have themselves
or their children tested even though family mem bers have had MTC. Others will have the test but
will choose to not treat family members who test
positive. Gagel speculated that these families probably believe that the disease is not tl at serious
because no family member has died of it in recent
memory. He emphasized, however, chat MTC is
very unpredictable and could suddenly turn deadly
in the next generation. He and his colleagues at
M. D. Anderson always take the time to help
families understand the risk. They discuss with
affected individuals and their family members the
advantages and disadvantages of the test and the
surgery. A pamphlet describing the test and the
treatment is provided to all families.
Gagel noted that studies going on at M. D.
Anderson and other institutions will allow even
more precise targeting of who should have the
test and who does not need to. "We expect that
future discoveries will allow us to predict more
accurately who will get the disease and how the
tumor will behave. This knowledge should also
allow us to refine our treatment strategies." Gagel
and Cote have worked closely with Maher Al bi tar,
M.D., director of the Molecular Diagnostics Laboratory in the Division of Laboratory Medicine, to
make the test available to clinicians.
A paradigm for genetic testing
Gagel sees the test for the RET mutation as a
model for understanding not only the medical
and surgical implications of genetic tests that
accurately predict cancer development, but also
the ethical, psychosocial, and financial implica tions. The development of the genetic test moved
so quickly from the discovery of the mutation
continued on page 5
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New trial reflects changing strategies

Adjuvant chemotherapy for breast
ancer: 20 years of progress at M. D.
Anderson
Today, more than two decades after it was first
tested in clinical trials, adjuvant chemotherapy is
widely used to reduce the risk of recurrence in
patients with operable breast cancer. The term
"adjuvant chemotherapy" refers to chemotherapy
administered after the primary tumor has been
treated by surgery or a combination of surgery
and radiotherapy. By destroying micro metastases
that remain after this local therapy, adjuvant chemotherapy can prevent disease recurrence, thus
prolonging patients' disease-free and overall survival. Two drug regimens-CMF, a combination
of cyclophosphamide, methotrexate, and 5-fluorouracil; and FAC, a combination of 5-fluorouracil, doxorubicin (Adriamycin), and
cyclophosphamide-and their variations have
emerged as the most widely used adjuvant chemotherapy regimens for breast cancer patients.
Doxorubicin gives breast cancer therapy a
boost
When researchers at The University of Texas
M. D. Anderson Cancer Center began their clinical trials of adjuvant chemotherapy for breast
cancer in 1973, they chose to study doxorubicin.
At that time, several studies suggested that doxorubicin was the most effective chemotherapeutic
agent against metastatic breast cancer. Over the
past 21 years, the researchers have continued to
focus on doxorubicin in combination regimens in
the adjuvant setting. Leading their studies of
doxorubicin today is Aman U. Buzdar, M.D.,
chief of adjuvant protocols and deputy chairman
of the Department of Breast and Gynecologic
Medical Oncology.
"In 1974, when we started the studies here,
there was no clear evidence that any patient would
be cured with adjuvant therapies," said Buzdar.
"We gave the FAC combination to patients with
macroscopic metastatic disease where we could
see the response-for instance, to patients with
lung tumors, which we could see on chest x-rays.
When we gave those patients chemotherapy, about
20% of the time the cancer completely disappeared, and another 50% to 60% of the time, the
cancer shrank to less than half of its original size.

This was the first time we had a drug combination that worked 70% to 80% of the time.
"We moved that combination to the adjuvant
setting for patients at very high risk of disease
recurrence . We wanted to see whether any of
these patients could be kept free of disease."
Whereas most of the studies going on at the
national level in the early 1970s, said Buzdar,
were testing one, two, or three drugs at low
doses, Buzdar and his colleagues administered
the FAC combination at relatively high doses,
with good results. "We were pleasantly surprised
that there was a sizable fraction of patients who
were free of disease beyond three, four, and even
five years."
Clinical trials led to improved treatments
From 1974 to 1990, Buzdar and his colleagues
carried out this first trial plus four other major
clinical trials of regimens containing doxorubicin. Guided by the results from these trials, Buzdar
and his colleagues have been able to design new
treatments that are both more effective and less
toxic than the early FAC regimen and its variants.
One of the ways the M. D. Anderson investigators sought to improve the effectiveness of the
FAC combination was to alter the dose of doxorubicin. "We were trying to push . the dose of
chemotherapy to see whether we could further
reduce the risk of recurrence," recalled Buzdar.
"At doses above 60 mg/m2 , we've found that
there is not much therapeutic gain, but the toxicity is substantial."
In the early 1970s, when the first trials of
adjuvant chemotherapy were beginning across
the nation, physicians were concerned about
doxorubicin's long-term effects on the heart.
"Long-term data, with follow-up of over 20 years,
indicate that doxorubicin will cause problems in
only about 1 % of patients," noted Buzdar. Over
a decade ago, Buzdar and his colleagues made
this risk even smaller by beginning to administer
the drug by continuous infusion over a three-day
period. "We have found that this substantially
reduces the risk of damage to the heart. Some
patients still say they don't want to take the risk

Treatment Update

Aman U. Buzdar is chief of
adjuvant protocols and
deputy chairman of the
Department of Breast and
Gynecologic Medical
Oncology

continued on page 4
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"I think that at every stage of disease,
patients are doing better now than they
were doing 20 years ago."
of cardiac dysfunction, but the benefit, I think,
outweighs the risk."
The acute side effects associated with doxoru bicin in the early trials included reversible hair
loss, nausea, and vomiting. Patients still lose their
hair, said Buzdar, but nausea and vomiting are no
longer a problem for the huge majority of patients. "In the past few years, extremely effective
antiemetics have become available. Ninety-nine
percent of the time we can control the nausea and
vomiting."
One of the major unresolved questions today
in the field of adjuvant chemotherapy for breast
cancer is whether regimens that contain
anthracyclines-doxorubicin in the United States
and epirubicin, a doxorubicin analogue, in Europe-are superior to the CMF regimen and its
variants. According to Buzdar, the current trend
in the United States is to treat high-risk patients-those with four or more disease-positive
lymph nodes-with FAC-type regimens. However, for patients with fewer than four positive
nodes, many physicians still favor CMF-type regi·mens.
At M. D. Anderson, the disease-free and overall survival rates for patients treated with doxoru bicin-based regimens have been higher, in some
cases significantly higher, than th_e rates for patients treated with CMF-type regimens at other
institutions. On the basis of these results, Buzdar
believes that regimens that include doxorubicin
are probably superior for both high- and low-risk
subgroups. He concedes, however, that there is
not yet enough evidence of their superiority in
patients with fewer than four positive nodes. "My
bias and the bias in this institution is that even in
low-risk subgroups the doxorubicin-based combinations will be superior. But to show that, and
· to convince the community at large, will require
a lot of effort and resources. Because the risk of
recurrence in this subgroup is small, we will need
studies with thousands of patients to show significant survival advantages."
New trial tests less radical surgery
Today, Buzdar and his colleagues continue to
search for new treatments that will be more effective and more tolerable for patients. They have
just begun a complex trial. "In this trial we are
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trying to answer two major questions," said
Buzdar. "Will giving a new drug before the FAC
treatment further improve the odds of patients'
remaining free of cancer? Can we do less radical
surgery and still achieve the same survival results
in the long run?"
The trial is open to patients with T 2_3 , N 0_p M 0
invasive, non-inflammatory breast cancer. This
means that patients with tumors up to 5 cm or
even larger are eligible, as long as they have no
distant metastases and their axillary lymph nodes,
if affected, are not fixed together. Buzdar and his
colleagues plan to enroll about 500 patients over
a period of about five years.
In addition to surgery and adjuvant chemotherapy, patients in this trial will be treated with
neoadjuvant chemotherapy, which is administered
before surgery with the goal of shrinking the
tumor and any affected lymph nodes. At the
outset of the trial, patients will be randomized to
receive before surgery either four cycles of FAC
or four cycles of paclitaxel (Taxol), a very active
drug that was first tested in clinical trials in 1983.
After two cycles, patients in both groups will
be evaluated, and those with evidence of progressive disease will be switched to the other group
for the remaining two cycles. After the completion of all four cycles, patients will be evaluated
again.
If the tumor has not shrunk significantly or if
there is evidence of axillary lymph node metastases,
patients will undergo mastectomy followed by
four cycles of FAC and then radiotherapy. Following completion of this treatment, patients
older than 50 whose tumors are estrogen-receptor positive will receive tamoxifen, an antiestrogen
shown to prolong disease-free and overall survival in this subgroup, for five years.
If the tumor has shrunk significantly and there
is no clinical evidence of axillary lymph node
metastases, patients will be randomized to un dergo either segmental mastectomy and axillary
dissection or segmental mastectomy alone. In a
segmental mastectomy, the breast is conserved;
the surgeon removes only the tumor and, to
ensure that all of the cancerous tissue is removed,
a small margin of normal tissue immediately surrounding the tumor. Segmental mastectomy plus
axillary lymph node dissection, on the other hand,
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is a more extensive procedure and one that results

in greater discomfort and disfigurement for the
patient.
After surgery, patients in the two segmental
mastectomy groups, like those in the mastectomy
group, will receive four cycles of FAC and then
radiotherapy. Again, patients older than 50 whose
tumors are estrogen-receptor positive will receive
tamoxifen for five years.
Buzdar hopes that follow-up data will show
segmental mastectomy alone followed by irradiation of the intact lymph nodes to be as effective
as segmental mastectomy with axillary dissection.
"Segmental mastectomy alone is a very simple
procedure," said Buzdar. "It can be done on an
outpatient basis. It is much less disfiguring, and
if it allows similar survival outcomes, it will be
much better for patients in the long run." As for
the effectiveness of the combination of FAC and
paclitaxel over FAC alone, "that's another million -dollar question."
Asked what kinds of gains in survival he envisioned as a result of improved methods of adju-

vant chemotherapy in the next 20 years, Buzdar
was cautiously optimistic. "I wish I had a crystal
ball. The thing is, we're making slow progress.
We're hoping that with the new strategies we're
trying now, we'll see some gains. In spite of our
best efforts, a substantial proportion of patients
still die of their disease. So there is a lot of room
for improvement." But also room for optimism:
"I think that at every stage of disease, patients are
doing better now than they were doing 20 years
ago. And I think we can definitely say that, based
on 20 years of follow-up, there is a fraction of
patients who can be cured py local therapy and
adjuvant chemotherapy."
-STEPHANIE

P.

DEMING

REFERRALS. Physicians who have questions or
would like to refer a patient may write Dr. Buzdar,
Department of Breast and Gynecologic Medical
Oncology, Box 56, The University of Texas M. D.
Anderson Cancer Center, 1515 Holcombe Blvd.,
Houston, Texas 77030, or call (713) 792-2817. ■

Medullary thyroid carcinoma
contin ued from page 2

that even medical professionals are not in agreement about the appropriate uses of the test. Despite the inevitable controversies surrounding
genetic testing, there is good news for families
affected by MEN 2. The RET mutation test is a
case of a new technology improving cancer pa tients' chances of cure at a lower cost. Even a
crude cost analysis shows that the one-time test
and surgery are cheaper than the annual battery
of screening tests, which are usually recommended
for individuals at risk until the age of 35 years.
Test offers a better life
ust as t
their children tested for the mutation, they knew
immediately when Gagel offered thyroidectomy

as a treatment option that they wanted their child
to have the surgery. As Cathy said, "Why take the
chance that the child will develop metastasis? I've
lived without my thyroid for 20 years and it's no
big deal. We believe the surgery was the best
choice we could make to prevent future illness.
There's no question in my mind that this test and
the surgery have improved the quality of my life
and of my son's."
-KATHRYN L. HALE
REFERRALS. Physicians who have questions or
would like to refer a patient may write Dr. Gagel at the
n ocnne ectJ.on, ox
e mvers1ty o exas
M. D. Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, TX 77030, or call (713) 792-2840. ■

he blood test for the RET mutation is available to patients who are referred to the Endocrine
Section of M . D. Anderson Cancer Center and to their families. Said Robert F. Gagel, chief
of the section, "We believe that all patients with medullary thyroid carcinoma should have this
test, and we have made it available in our clinical laboratory." He added, "It is important to
perform this analysis on all patients with MTC, regardless of whether the disease is thought to
be familial, because of the important implications for children and other family members if the
test is positive."

T
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"We have organized the outpatient clinic to offer
the cutting edge of developing therapies in a
convenient fashion."

Bone marrow
continued from page 8
high-dose chemotherapy courses and transplantations in a comfortable, cost-effective setting
that could be made available to large numbers of
patients, Champlin last summer pioneered the
opening of the Outpatient Clinic for Bone Marrow Transplantation, giving patients who require
such treatment a much greater degree of freedom
than they ever had before. "Transplantation in an
outpatient setting," Champlin explained, "takes
an otherwise restrictive and expensive procedure
and not only makes it more tolerable for the
patients but also actually permits the use of the
more effective high-dose treatment strategies."
Outpatient transplantation more flexible,
less expensive
By using the Outpatient Clinic for Bone Marrow Transplantation at M. D. Anderson, patients
needing autologous transplantation can bypass
much of the stay in the hospital. Typically, patients achieve clinical stability about three days
after they receive high-dose therapy. At this point,
they can be discharged from inpatient care to the
outpatient clinic. The next morning the patient
can receive an autologous transplant in the outpatient clinic and return home by midday. The
patient is cared for at home by a family member
or a professional caregiver and returns to the
clinic every day for about a month for monitoring.
Patients requiring allogeneic transplantation
can also be treated in the out atient clinic. This
more complicated procedure requires that the
proteins on the surfaces of the stem cells of pa tients be matched with those of the donors. An
exact match is impossible, and the greater number of side effects in this group is due to slight
mismatches in the proteins. Patients undergoing
allogeneic transplantation therefore receive both
their high-dose therapy and their transplant as
inpatients, spending about one month in the
hospital. They can then be enrolled as outpatients
in the clinic and are monitored three times a week
for an additional three weeks after they receive
their transplant.
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Support services in the outpatient clinic are as
extensive as those for inpatients. A team composed of a physician, clinical nurse specialist, and
clinical pharmacist is assigned to each patient.
Psychological and psychiatric support is available
twenty-four hours a day. M. D. Anderson is always ready to readmit the patient, and antibiotic
infusions and blood transfusions are immediately
available. At any time for any problem, the patient can be seen at the Ambulatory Treatment
Center for Acute Care in the hospital or can call
the M. D. Anderson primary physician. During
the clinic's first year of operation, no major complications or deaths occurred in outpatients.
The success of bone marrow transplantation
depends on careful monitoring until the patient is
clinically stable and the blood counts have returned to normal levels. The most significant risk
for these immunocompromised patients, infec-tion, is minimized by administering hematopoietic growth factors that help new marrow develop
faster. The risk of infection is probably as great
for a hospitalized patient as for a patient cared for
at home, indicated Champlin.
The Section of Bone Marrow Transplantation
has organized the outpatient clinic to offer the
cutting edge of developing therapies in a convenient fashion. Champlin emphasized, "Our goal
is to cure the cancer, not just to reduce the costthe cost reduction is an added bonus." The outpatient clinic reduces the cost of bone marrow
transplantation by 50% and the length of hospital
stay by 100% for autologous transplantation and
50% for allogeneic transplantation. These reductions make it realistic and practical to offer a series
of su ortive trans lants.
Many patients eligible for outpatient
transplantation
The clinic's first patients were women with
breast cancer who were suspected of having
metastases. Their peripheral-blood stem cellswhich allow blood counts to return to normal
levels faster than bone marrow cells-were first
collected and stored for future autologous transplantation. These women then underwent four
monthly courses of treatment that included a
two- to three-day inpatient stay for chemotherapy
and a one- to four-hour outpatient stay for stem
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"Transplantation in the clinic can be integrated
with surgery, chemotherapy, or radiotherapy to
optimize therapeutic effectiveness."
cell infusion. This series of treatments is much
more effective than a single high-dose course
followed by bone marrow transplantation-and
in the outpatient clinic costs the same as a single
inpatient treatment.
The outpatient clinic also treats patients with
ovarian cancer, lymphoma, multiple myeloma, or
leukemia. Transplantation in the clinic can be
integrated with other treatment-surgery, chemotherapy, or radiotherapy-to optimize thera peutic effectiveness. The clinic is designed to
extend the treatment that patients receive from
their personal physicians; thus, referring doctors
can now manage their patients' care in concert
with the Outpatient Clinic for Bone Marrow
Transplantation. There is no waiting period for
patients with disease that requires immediate care.
To be eligible for the outpatient program,
patients must be able to reside within a 30-mile
radius of M. D. Anderson during treatment and
have a companion to assist in their care. Although
older patients have tradition ally been excluded
from bone marrow transplantation, the outpa -

tient clinic treats patients up to the age of 65
years when their medical condition is appropriate
for the procedure.
Acknowledging the additional burden placed
on caregivers at home as a result of outpatient
treatment, Champlin said that he was pleasantly
surprised by the favorable response of patients
and their families. Nearly one third of the bone
marrow transplantations performed by M. D.
Anderson are now received by outpatients.
Champlin suggested that "whereas a lengthy
hospital stay compromises a patient's sense of
freedom, treatment in the outpatient clinic does
not."
-LINDA

N.

EPPICH

REFERRALS. Physicians who have questions or
would like to refer a patient may write Dr. Champlin,
Section of Bone Marrow Transplantation, Box 65,
The University ofTexas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, or
call (713) 792-3611. ■
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Procedure allows patients to tolerate higher doses of therapy

mawow transplantation now
available as an outpatient procedure

Bone
Patient Care

Richard E. Champlin is
chief of the Section of
Bone Marrow
Transplantation

Certain typ s of cancer re pond w 11 to ry
high doses of chemotherap and radioth rap
but these high doses cause lethal damag to th
bone marrow. Bone marrow transplantation ha
been used for over a decade to r plac th
damaged blood-forming tissues, but until r c ntl
this procedure required a length , expen i ho pital stay to await reco ery of the patient's immune system as the transplant took £feet. At th
Outpatient Clinic for Bone Marrow Transplantation at The University of Texas M. D. Anderson
Cancer Center, however, a patient can be infused
with stem cells or bone marrow in the morning
and be home in time for lunch.
Conventional transplantation impossible for
some
Patients undergoing conventional transplantation remain hospitalized for the duration of the
procedure. The patient first recei es high-dose
therapy to eradicate the tumor. In cases of autologous transplantation, that is, infusion of the
patient's own stem cells that were remo ed be-
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Further complicating matter
aid Richard E.
Champlin, chief of the Section of Bone Marro
Transplantation at M. D. Ander on Cancer Center, a series of high-dose chemotherap cour e i
often more effecti e than a single treatment, necessitating a corresponding serie of supporti e
bone marrow transplants.
The length hospital sta s and high costs ha e,
in the past, made treatment protocol that require bone marrow transplantation impractical
from the viewpoints of both the patient and the
pa er. Looking for a wa to gi e the e serie of
continued on page 6

